domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -39,3 +39,10 @@ Omada Health's 3x growth in GLP-1 members over 12 months (reaching 150K members)
 **Source:** Omada Health clinical data, JMIR publication
 
 Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% for standard care, representing a 20-percentage-point improvement. This data is from JMIR-published research and is now validated at commercial scale with 150K+ members in the GLP-1 track as of early 2026.
+
+
+## Extending Evidence
+
+**Source:** Noom 2025 performance data, Pharmaceutical Commerce
+
+Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks, with December cohort D30 engagement at 43.6% (10x+ higher than average health/medical/fitness app retention of 4.3%). The company identified side effect management during titration phase as primary cause of 30%+ dropout in first 4 weeks. Noom's microdose strategy addresses adherence at the biological source (lower dose → fewer side effects) rather than purely behavioral intervention, suggesting that pharmaceutical design innovation may be as important as behavioral support for persistence.

inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md

@@ -7,10 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: news
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-28
 priority: medium
 tags: [noom, GLP-1, behavioral-support, biomarker, digital-health, adherence, microdose]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content